Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgery Today

19-04-2024 | Cytostatic Therapy | Original Article

Effects of transmembrane serine protease 4 on the survival in patients with pancreatic ductal adenocarcinoma undergoing surgery followed by adjuvant chemotherapy

Authors: Sho Tazuma, Takeshi Sudo, Akira Ishikawa, Atsushi Yamaguchi, Yoshiyuki Shibata, Yuko Ishida, Kazuya Kuraoka, Kenichiro Uemura, Shinya Takahashi, Hirotaka Tashiro

Published in: Surgery Today

Login to get access

Abstract

Purpose

The transmembrane serine protease 4 (TMPRSS4) gene is upregulated in various human cancers. However, its biological functions in pancreatic ductal adenocarcinoma remain unclear. We examined the expression of TMPRSS4 in pancreatic ductal adenocarcinoma tissues and its correlation with clinicopathological parameters in patients with pancreatic ductal adenocarcinoma who underwent surgery.

Methods

The TMPRSS4 expression was immunohistochemically examined in 81 PDAC patients with pancreatic ductal adenocarcinoma. We analyzed the association between the TMPRSS4 expression and clinicopathological factors, the recurrence-free survival (RFS), and the overall survival (OS) and examined the effect of TMPRSS4 expression on cell migration and sensitivity to 5-fluorouracil.

Results

The expression rate of TMPRSS4 in the samples was 62.9% (51/81). The TMPRSS4 expression was not correlated with any clinicopathological feature. The five-year overall and recurrence-free survival rates were significantly lower in the TMPRSS4-positive group than in the TMPRSS4-negative group. On a multivariate analysis, TMPRSS4 positivity, poorly differentiated histology, and non-adjuvant chemotherapy predicted a poor OS, while TMPRSS4 positivity and poorly differentiated histology predicted a poor RFS. TMPRSS4-silenced pancreatic ductal adenocarcinoma cells showed higher sensitivity to 5- fluorouracil than did the control siRNA-transfected cells.

Conclusions

TMPRSS4 can be considered a prognostic factor and therapeutic target for pancreatic ductal adenocarcinoma.
Appendix
Available only for authorised users
Literature
1.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.CrossRefPubMed
2.
Moon HJ, An JY, Heo JS, Choi SH, Joh JW, Kim YI. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas. 2006;32:37–43.CrossRefPubMed
3.
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAM. 2007;297:267–77.CrossRef
4.
Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRefPubMed
5.
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–24.CrossRefPubMed
6.
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.CrossRefPubMed
7.
8.
Wallrapp C, Hähnel S, Müller-Pillasch F, Burghardt B, Iwamura T, Ruthenbürger M, et al. A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res. 2000;60:2602–6.PubMed
9.
Huang A, Zhou H, Zhao H, Quan Y, Feng B, Zheng M. High expression level of TMPRSS4 predicts adverse outcomes of colorectal cancer patients. Med Oncol. 2013;30:712.CrossRefPubMed
10.
Liang B, Wu M, Bu Y, Zhao A, Xie F. Prognostic value of TMPRSS4 expression in patients with breast cancer. Med Oncol. 2013;30:497.CrossRefPubMed
11.
Wu XY, Zhang L, Zhang KM, Zhang MH, Ruan TY, Liu CY, et al. Clinical implication of TMPRSS4 expression in human gallbladder cancer. Tumour Biol. 2014;35:5481–6.CrossRefPubMed
12.
Wang CH, Guo ZY, Chen ZT, Zhi XT, Li DK, Dong ZR, et al. TMPRSS4 facilitates epithelial-mesenchymal transition of hepatocellular carcinoma and is a predictive marker for poor prognosis of patients after curative resection. Sci Rep. 2015;5:12366.CrossRefPubMedPubMedCentral
13.
Chikaishi Y, Uramoto H, Koyanagi Y, Yamada S, Yano S, Tanaka F. TMPRSS4 expression as a marker of recurrence in patients with lung cancer. Anticancer Res. 2016;36:121–7.PubMed
14.
Tazawa H, Suzuki T, Saito A, Ishikawa A, Komo T, Sada H, et al. Utility of TMPRSS4 as a prognostic biomarker and potential therapeutic target in patients with gastric cancer. J Gastrointest Surg. 2022;26:305–13.CrossRefPubMed
15.
16.
Zeng P, Zhang P, Zhou LN, Tang M, Shen YX, Jin J, et al. TMPRSS4 as an emerging potential poor prognostic factor for solid tumors: a systematic review and meta-analysis. Oncotarget. 2016;7:76327–36.CrossRefPubMedPubMedCentral
17.
Kim S, Kang HY, Nam EH, Choi MS, Zhao XF, Hong CS, et al. TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways. Carcinogenesis. 2010;31:597–606.CrossRefPubMed
18.
Gu J, Huang W, Zhang J, Wang X, Tao T, Yang L, et al. TMPRSS4 promotes cell proliferation and inhibits apoptosis in pancreatic ductal adenocarcinoma by activating ERK1/2 signaling pathway. Front Oncol. 2021;11: 628353.CrossRefPubMedPubMedCentral
19.
Brierley JD, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC): TNM Classification of Malignant Tumors. Hoboken: John wiley & sons; 2017.
20.
21.
22.
Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–63.CrossRefPubMed
23.
Safley DM, Amin AP, House JA, Baklanov D, Mills R, Giersiefen H, et al. Comparison of costs between transradial and transfemoral percutaneous coronary intervention: a cohort analysis from the Premier research database. Am Heart J. 2013;165:303-9.e2.CrossRefPubMed
24.
Ye H, Li T, Wang H, Wu J, Yi C, Shi J, et al. TSPAN1, TMPRSS4, SDR16C5, and CTSE as novel panel for pancreatic cancer: a bioinformatics analysis and experiments validation. Front Immunol. 2021;12: 649551.CrossRefPubMedPubMedCentral
25.
Bhasin MK, Ndebele K, Bucur O, Yee EU, Otu HH, Plati J, et al. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier. Oncotarget. 2016;7:23263–81.CrossRefPubMedPubMedCentral
26.
Cheng Y, Wang K, Geng L, Sun J, Xu W, Liu D, et al. Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma. EBioMed. 2019;40:382–93.CrossRef
27.
Cheng H, Fukushima T, Takahashi N, Tanaka H, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res. 2009;69:1828–35.CrossRefPubMed
28.
Exposito F, Villalba M, Redrado M, de Aberasturi AL, Cirauqui C, Redin E, et al. Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery. Cancer Lett. 2019;453:21–33.CrossRefPubMed
29.
Maehara Y, Kusumoto T, Kusumoto H, Anai H, Sakaguchi Y, Kido Y, et al. 5-fluorouracil and UFT-sensitive gastric carcinoma has a high level of thymidylate synthase. Cancer. 1989;63:1693–6.CrossRefPubMed
30.
Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, et al. Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection. J Surg Oncol. 2011;104:146–54.CrossRefPubMed
31.
Oba A, Ban D, Kirimura S, Akahoshi K, Mitsunori Y, Matsumura S, et al. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Hepato Pancreat Sci. 2016;23:480–8.CrossRef
32.
Kurata N, Fujita H, Ohuchida K, Mizumoto K, Mahawithitwong P, Sakai H, et al. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. Int J Oncol. 2011;39:473–82.PubMed
33.
Kurasaka C, Ogino Y, Sato A. Molecular mechanisms and tumor biological aspects of 5-fluorouracil resistance in HCT116 human colorectal cancer cells. Int J Mol Sci. 2021;22:2916.CrossRefPubMedPubMedCentral
34.
Kurasaka C, Nishizawa N, Ogino Y, Sato A. Trapping of 5-Fluorodeoxyuridine monophosphate by thymidylate synthase confers resistance to 5-fluorouracil. ACS Omega. 2022;7:6046–52.CrossRefPubMedPubMedCentral
35.
Mori R, Yoshida K, Futamura M, Suetsugu T, Shizu K, Tanahashi T, et al. The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells. Gastric Cancer. 2019;22:497–505.CrossRefPubMed
36.
Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.CrossRefPubMed
37.
Van Triest B, Pinedo HM, Giaccone G, Peters GJ. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol. 2000;11:385–91.CrossRefPubMed
Metadata
Title
Effects of transmembrane serine protease 4 on the survival in patients with pancreatic ductal adenocarcinoma undergoing surgery followed by adjuvant chemotherapy
Authors
Sho Tazuma
Takeshi Sudo
Akira Ishikawa
Atsushi Yamaguchi
Yoshiyuki Shibata
Yuko Ishida
Kazuya Kuraoka
Kenichiro Uemura
Shinya Takahashi
Hirotaka Tashiro
Publication date
19-04-2024
Publisher
Springer Nature Singapore
Published in
Surgery Today
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-024-02824-y